Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18496626 | 0.86 | POLB (0.41) | JAK2ANO1ALOX5APFEN1POLB | |
| SCHEMBL18285347 | 0.86 | P2RY14 (0.49) | JAK2ANO1HDAC2P2RY14 | |
| SCHEMBL18285294 | 0.86 | CNR1 (0.46) | JAK2ANO1LMNATP53SCN10A | |
| SCHEMBL18285284 | 0.84 | CNR1 (0.37) | PTPN1NPC1RAB9ASCN10AHDAC2 | |
| SCHEMBL19656312 | 0.84 | SCN10A (0.47) | JAK2PTPN1ANO1MAPTLMNA | |
| SCHEMBL21003937 | 0.83 | AKR1C3 (0.41) | JAK2HTTLMNA | |
| SCHEMBL18285282 | 0.83 | JAK2 (0.45) | JAK2PTPN1ANO1NPC1HTT | |
| SCHEMBL29727626 | 0.83 | JAK2 (0.45) | JAK2PTPN1ANO1NPC1HTT | |
| SCHEMBL18285283 | 0.79 | SMN1; SMN2 (0.44) | HTTRAB9AMAPTLMNA | |
| SCHEMBL18706009 | 0.77 | P2RY14 (0.44) | JAK2ANO1MAPTLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563049-B | Imidazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-109071451-B | Pyrazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-107531642-B | Imidazole derivatives | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| CN-107922391-B | Pyridine and pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180162824-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| WO-2018069362-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018069362-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-19 | — | — | WO | disclosed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017025523-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025523-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162824-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | MC3R, MC2R, NPY1R | JAK2 564/4885PTPN1 1018/4885ANO1 902/4885 |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | DRD3, GABRR3, DRD4 | JAK2 694/4885PTPN1 2548/4885ANO1 1134/4885 |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | JAK2 145/4885PTPN1 3337/4885ANO1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.